1716 related articles for article (PubMed ID: 9828245)
1. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
Furlan M; Robles R; Galbusera M; Remuzzi G; Kyrle PA; Brenner B; Krause M; Scharrer I; Aumann V; Mittler U; Solenthaler M; Lämmle B
N Engl J Med; 1998 Nov; 339(22):1578-84. PubMed ID: 9828245
[TBL] [Abstract][Full Text] [Related]
2. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.
Furlan M; Lämmle B
Best Pract Res Clin Haematol; 2001 Jun; 14(2):437-54. PubMed ID: 11686108
[TBL] [Abstract][Full Text] [Related]
3. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.
Tsai HM; Lian EC
N Engl J Med; 1998 Nov; 339(22):1585-94. PubMed ID: 9828246
[TBL] [Abstract][Full Text] [Related]
4. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP).
Gerritsen HE; Turecek PL; Schwarz HP; Lämmle B; Furlan M
Thromb Haemost; 1999 Nov; 82(5):1386-9. PubMed ID: 10595623
[TBL] [Abstract][Full Text] [Related]
5. Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura.
Furlan M
Expert Rev Cardiovasc Ther; 2003 Jul; 1(2):243-55. PubMed ID: 15030284
[TBL] [Abstract][Full Text] [Related]
6. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity.
Mori Y; Wada H; Gabazza EC; Minami N; Nobori T; Shiku H; Yagi H; Ishizashi H; Matsumoto M; Fujimura Y
Transfusion; 2002 May; 42(5):572-80. PubMed ID: 12084165
[TBL] [Abstract][Full Text] [Related]
7. Assays of von Willebrand factor-cleaving protease: a test for diagnosis of familial and acquired thrombotic thrombocytopenic purpura.
Furlan M; Lämmle B
Semin Thromb Hemost; 2002 Apr; 28(2):167-72. PubMed ID: 11992240
[TBL] [Abstract][Full Text] [Related]
8. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura.
Furlan M; Robles R; Solenthaler M; Wassmer M; Sandoz P; Lämmle B
Blood; 1997 May; 89(9):3097-103. PubMed ID: 9129011
[TBL] [Abstract][Full Text] [Related]
9. Two novel ADAMTS13 gene mutations in thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/HUS).
Licht C; Stapenhorst L; Simon T; Budde U; Schneppenheim R; Hoppe B
Kidney Int; 2004 Sep; 66(3):955-8. PubMed ID: 15327386
[TBL] [Abstract][Full Text] [Related]
10. Deficiency of von Willebrand factor-cleaving protease in familial and acquired thrombotic thrombocytopenic purpura.
Furlan M; Lämmle B
Baillieres Clin Haematol; 1998 Jun; 11(2):509-14. PubMed ID: 10097823
[TBL] [Abstract][Full Text] [Related]
11. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
Sarkodee-Adoo C; Gojo I; Heyman MR
N Engl J Med; 1999 Apr; 340(17):1368; author reply 1369. PubMed ID: 10223876
[No Abstract] [Full Text] [Related]
12. von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.
Remuzzi G; Galbusera M; Noris M; Canciani MT; Daina E; Bresin E; Contaretti S; Caprioli J; Gamba S; Ruggenenti P; Perico N; Mannucci PM;
Blood; 2002 Aug; 100(3):778-85. PubMed ID: 12130486
[TBL] [Abstract][Full Text] [Related]
13. Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome.
Moake JL
Arch Pathol Lab Med; 2002 Nov; 126(11):1430-3. PubMed ID: 12421153
[TBL] [Abstract][Full Text] [Related]
14. [Hemolytic uremic syndrome and thrombotic thrombocytopenic purpura].
Masset C; Dubois B; Rorive G
Rev Med Liege; 2002 Jan; 57(1):33-9. PubMed ID: 11899496
[TBL] [Abstract][Full Text] [Related]
15. The "cutting" edge: von Willebrand factor-cleaving protease activity in thrombotic microangiopathies.
Haspel RL; Jarolím P
Transfus Apher Sci; 2005 Apr; 32(2):177-84. PubMed ID: 15784452
[TBL] [Abstract][Full Text] [Related]
16. von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome.
Tsai HM; Chandler WL; Sarode R; Hoffman R; Jelacic S; Habeeb RL; Watkins SL; Wong CS; Williams GD; Tarr PI
Pediatr Res; 2001 May; 49(5):653-9. PubMed ID: 11328948
[TBL] [Abstract][Full Text] [Related]
17. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura.
Furlan M; Robles R; Morselli B; Sandoz P; Lämmle B
Thromb Haemost; 1999 Jan; 81(1):8-13. PubMed ID: 10348715
[TBL] [Abstract][Full Text] [Related]
18. Thrombotic thrombocytopenic purpura attributable to von Willebrand factor-cleaving protease inhibitor in an 8-year-old boy.
Robson WL; Tsai HM
Pediatrics; 2002 Feb; 109(2):322-5. PubMed ID: 11826215
[No Abstract] [Full Text] [Related]
19. Recent advances in thrombotic thrombocytopenic purpura.
Sadler JE; Moake JL; Miyata T; George JN
Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695
[TBL] [Abstract][Full Text] [Related]
20. Complete defect in vWF-cleaving protease activity associated with increased shear-induced platelet aggregation in thrombotic microangiopathy.
Ajzenberg N; Denis CV; Veyradier A; Girma JP; Meyer D; Baruch D
Thromb Haemost; 2002 May; 87(5):808-11. PubMed ID: 12038781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
